Induction Nivolumab Before Chemoradiation in High-Risk Human Papillomavirus-Driven Oropharynx Cancers: IMMUNEBOOST-HPV, a Multicenter Randomized Phase II Trial.

Key Points

• This research aimed to evaluate the feasibility and impact of nivolumab induction prior to chemoradiation in patients with high-risk HPV-related oropharynx cancers.
• Conducted a multicenter randomized phase II trial.
• Administered nivolumab before standard chemoradiation (CRT) treatment.
• Monitored toxicity and relapse incidence among participants.
• Nivolumab induction did not meet the feasibility threshold due to reduced cisplatin dosing in 10% of patients.
• The relapse incidence was numerically lower in the experimental arm, but this finding remains exploratory.